Australia markets open in 7 hours 25 minutes

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
23.23-0.43 (-1.82%)
At close: 03:04PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 12.39B
Enterprise value 11.18B
Trailing P/E 39.09
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)14.06
Price/book (mrq)5.46
Enterprise value/revenue 12.69
Enterprise value/EBITDA 31.02

Trading information

Stock price history

Beta (5Y monthly) 0.53
52-week change 3-34.91%
S&P500 52-week change 323.49%
52-week high 341.94
52-week low 318.44
50-day moving average 324.06
200-day moving average 327.05

Share statistics

Avg vol (3-month) 35.33M
Avg vol (10-day) 35.07M
Shares outstanding 5523.58M
Implied shares outstanding 6530.73M
Float 8205.41M
% held by insiders 150.82%
% held by institutions 117.99%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.2
Forward annual dividend yield 40.85%
Trailing annual dividend rate 30.19
Trailing annual dividend yield 30.78%
5-year average dividend yield 40.46
Payout ratio 433.04%
Dividend date 3N/A
Ex-dividend date 406 July 2023
Last split factor 21.8:1
Last split date 308 May 2019

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 35.96%
Operating margin (ttm)34.53%

Management effectiveness

Return on assets (ttm)8.07%
Return on equity (ttm)13.51%

Income statement

Revenue (ttm)881.3M
Revenue per share (ttm)1.68
Quarterly revenue growth (yoy)18.10%
Gross profit (ttm)N/A
EBITDA 348.84M
Net income avi to common (ttm)316.91M
Diluted EPS (ttm)0.61
Quarterly earnings growth (yoy)9.50%

Balance sheet

Total cash (mrq)1.28B
Total cash per share (mrq)2.45
Total debt (mrq)75.91M
Total debt/equity (mrq)3.18%
Current ratio (mrq)9.85
Book value per share (mrq)4.33

Cash flow statement

Operating cash flow (ttm)341.93M
Levered free cash flow (ttm)73.44M